Moderna has terminated its collaboration with CRISPR company Metagenomi, a partnership potentially valued up to $3 billion. This decision comes three years after Moderna invested in gene editing, using funds from its vaccine success. The biotech firm also parted ways with its top gene editing executive. The breakup with Metagenomi marks a significant shift in Moderna's strategy towards gene editing technologies. The nonprofit sector has stepped up to develop a platform for CRISPR LNP medicines, addressing rare challenges.
Moderna and Metagenomi are walking away from a partnership worth up to $3 billion. The move coincides with a strategic prioritization at Moderna. $MGX $MRNA https://t.co/esXv11oE5k
Moderna appears to see no current commercial value in a platform that can make CRISPR LNP medicines. This is why the nonprofit sector has stepped up. Such a platform exists and WILL be scaled to the N=1/rare challenge and SOON. Watch this space. #HealthJustice https://t.co/H53dZfP0Jz
Three years ago, Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it's backing out. https://t.co/VmTQ2TkDsX
Moderna $MRNA ends collaboration with CRISPR company Metagenomi $MGX, parts ways with gene editing chief https://t.co/40vgXaTLwz via @Jasonmmast
Three years ago, Moderna, flush with cash, announced it would start working on the burgeoning field of gene editing. Now, the company has broken off a collaboration with its main CRISPR partner $MGX and parted ways with its top gene editing executive https://t.co/YQyvXj3Tfh
Moderna breaks off deal with CRISPR company Metagenomi By @Jasonmmast https://t.co/6kQuqSQZAL